Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in Europe

4 references·2 citing·17 second hop

FromToDepth

this work references cited by second hop

References

2008Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma229 cited
2007Development trends for new cancer therapeutics and vaccines136 cited
2009Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?85 cited
2005Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 200361 cited

Cited by

2014Towards a sustainable system of drug development58 cited
2015Use of the conditional marketing authorization pathway for oncology medicines in Europe57 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work